Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00206596
Status:
COMPLETED
Last Update Posted:
2013-12-04
First Post:
2005-09-12
Brief Title:
Study in Patients With Crohns Disease Who Are Steroid Dependent Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohns Disease
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
Randomized Stratified Double-Blind Placebo-Controlled Phase 2 Study of Steroid-Sparing Properties of Sargramostim Leukine Therapy in Patients With Cortico-Dependent Crohns Disease
Status:
COMPLETED
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effectiveness of Leukine to decrease the need for steroid treatment for Crohns disease
Detailed Description:
On 29 May 2009 Bayer began transitioning the sponsorship of this trial to Genzyme NOTE This study was originally posted by sponsor Berlex Inc Berlex Inc was renamed to Bayer HealthCare Inc
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Novel 2 | None | None | None |
| 91282 | None | None | None |